INmune therapy shows promise in Alzheimer’s, but cognitive test still to come

After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The study will be one of the first tests of the neuroinflammation theory as interest in the role of the immune system in neurodegenerative diseases continues to grow.

INmune Bio Inc. (NASDAQ:INMB), which announced the readout after market close Monday, gained $6.90 (78%) to $15.75 on Tuesday...